中國上城(02330.HK):預計年度淨虧500萬至1000萬元
格隆匯 3 月 16日丨中國上城(02330.HK)發佈公吿,預期集團截至2020年12月31日止年度的收益將較2019年度減少約66%,並將錄得公司擁有人應占未經審核虧損介乎人民幣500萬元至人民幣1000萬元,而2019年度則為公司擁有人應占經審核溢利約人民幣7418.4萬元。
公吿表示,公司收益及業績的預期減少主要由於本年度物業銷售收益較2019年減少;2019年公司於茂名的物業發展項目第三期竣工、交付量及已確認銷售增加;及全球爆發2019冠狀病毒病的不利影響,導致公司投資物業的公允值下降約人民幣1000萬元所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.